WO2002002616A1 - Nouveau polypeptide, gamma-cop13, et polynucleotide codant ce polypeptide - Google Patents
Nouveau polypeptide, gamma-cop13, et polynucleotide codant ce polypeptide Download PDFInfo
- Publication number
- WO2002002616A1 WO2002002616A1 PCT/CN2001/000961 CN0100961W WO0202616A1 WO 2002002616 A1 WO2002002616 A1 WO 2002002616A1 CN 0100961 W CN0100961 W CN 0100961W WO 0202616 A1 WO0202616 A1 WO 0202616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- polynucleotide
- gamma
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- a fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are replaced with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution
- the amino acid may or may not be encoded by the genetic code; or (II) such a type in which a group on one or more amino acid residues is substituted by other groups to include a substituent; or (III) such A type in which a mature polypeptide is fused to another compound (such as a compound that extends the half-life of a polypeptide, such as polyethylene glycol); or (IV) a type of polypeptide sequence in which an additional amino acid sequence is fused into a mature polypeptide (such as the leader sequence or secreted sequence or the sequence used to purify this polypeptide or protease sequence)
- such fragments, derivatives and analogs are considered to be within the knowledge of those skilled in the art.
- polynucleotide encoding a polypeptide refers to a polynucleotide that includes the polypeptide and a polynucleotide that includes additional coding and / or non-coding sequences.
- "strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1% SDS, 6 (TC; or (2) Add a denaturant during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Fi co ll, 42 ° C, etc .; or (3) only between two sequences Hybridization occurs only when the identity is at least 95%, and more preferably 97%.
- the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2 .
- Methods known to those skilled in the art can be used to construct expression vectors containing a DNA sequence encoding gamnia-COP13 and appropriate transcriptional / translational regulatory elements. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Molecular Cloning, a Laboratory Manual, cold Spring Harbor Laboratory. New York, 1989).
- the DNA sequence (J) can be efficiently linked to an appropriate promoter in an expression vector to guide mRNA synthesis. Representative examples of these promoters are: the lac or trp promoter of E.
- a peptide synthesizer (product of PE company) was used to synthesize the following peptides specific to a-C0P13:
- polynucleotides of the present invention can be used as probes to be fixed on a microarray or a DM chip (also called a "gene chip") for analyzing differential expression analysis and gene diagnosis of genes in tissues.
- a microarray or a DM chip also called a "gene chip”
- Gamma-C0P13 specific primers for RNA-polymerase chain reaction (RT-PCR) in vitro amplification can also detect the transcript of ga-a-C0P13.
- PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes.
- oligonucleotide primers of the present invention by a similar method, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
- Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne un nouveau polypeptide, une gamma-COP13, et un polynucléotide codant ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant la gamma-COP13.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU10317/02A AU1031702A (en) | 2000-06-14 | 2001-06-11 | A novel polypeptide-gamma-cop13 and a polynucleotide encoding thesame |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00116482.1 | 2000-06-14 | ||
| CN 00116482 CN1328004A (zh) | 2000-06-14 | 2000-06-14 | 一种新的多肽——gamma－COP13和编码这种多肽的多核苷酸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002002616A1 true WO2002002616A1 (fr) | 2002-01-10 |
Family
ID=4585886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2001/000961 Ceased WO2002002616A1 (fr) | 2000-06-14 | 2001-06-11 | Nouveau polypeptide, gamma-cop13, et polynucleotide codant ce polypeptide |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1328004A (fr) |
| AU (1) | AU1031702A (fr) |
| WO (1) | WO2002002616A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6121942B2 (ja) * | 2014-05-15 | 2017-04-26 | トヨタ自動車株式会社 | 植物のバイオマス量を増産させる遺伝子及びその利用方法 |
-
2000
- 2000-06-14 CN CN 00116482 patent/CN1328004A/zh active Pending
-
2001
- 2001-06-11 WO PCT/CN2001/000961 patent/WO2002002616A1/fr not_active Ceased
- 2001-06-11 AU AU10317/02A patent/AU1031702A/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| FEBS LETT., vol. 314, no. 2, 1992, pages 195 - 198 * |
| HUM. MOL. GENET., vol. 8, no. 13, 1999, pages 2387 - 2396 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1328004A (zh) | 2001-12-26 |
| AU1031702A (en) | 2002-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001090176A1 (fr) | Nouveau polypeptide, keratine humaine 45.87, et polynucleotide codant ce polypeptide | |
| WO2002002616A1 (fr) | Nouveau polypeptide, gamma-cop13, et polynucleotide codant ce polypeptide | |
| WO2002026796A1 (fr) | Nouveau polypeptide, recepteur humain 14.3 d'hormone de croissance, et polynucleotide codant ce polypeptide | |
| WO2002006337A1 (fr) | Nouveau polypeptide, hydroxyindole-o-methyl transferase humaine 12.43, et polynucleotide codant ce polypeptide | |
| WO2001092518A1 (fr) | Nouveau polypeptide, proteine humaine 9.5 associee a la ccr4, et polynucleotide codant ce polypeptide | |
| WO2001094537A2 (fr) | Nouveau polypeptide, nadh-ubiquinone oxydoreductase humaine 21.89, et polynucleotide codant ce polypeptide | |
| WO2002000823A2 (fr) | Nouveau polypeptide, proteine d'activation enzymatique ras gtp 9.57, et polynucleotide codant ce polypeptide | |
| WO2002004501A1 (fr) | Nouveau polypeptide, $g(b)-glucosaccharase humaine 11.88, et polynucleotide codant ce polypeptide | |
| WO2001066584A1 (fr) | Nouveau polypeptide, proteine humaine pax 9, et polynucleotide codant pour ce polypeptide | |
| WO2001096526A2 (fr) | Nouveau polypeptide, facteur humain 11.77 d'inhibition tumorale, et polynucleotide codant ce polypeptide | |
| WO2001070783A1 (fr) | Nouveau polypeptide, proteine humaine gamma-cop 16, et polynucleotide codant pour ce polypeptide | |
| WO2001070965A1 (fr) | Nouveau polypeptide, facteur humain de regulation de la transcription 15, et polynucleotide codant pour ce polypeptide | |
| WO2002002768A1 (fr) | Nouveau polypeptide, recepteur peptidique natriuretique humain 9, et polynucleotide codant ce polypeptide | |
| WO2001090172A1 (fr) | Nouveau polypeptide, proteine ribosomale l39 13, et polynucleotide codant ce polypeptide | |
| WO2002026971A1 (fr) | Nouveau polypeptide, facteur de transcription humain lcr-f112.1, et polynucleotide codant ce polypeptide | |
| WO2001090131A1 (fr) | Nouveau polypeptide, proteine humaine 10.56 du gene cancerigene tre, et polynucleotide codant ce polypeptide | |
| WO2001092516A1 (fr) | Nouveau polypeptide, proteine ribosomale s19e 13, et polynucleotide codant ce polypeptide | |
| WO2001090379A1 (fr) | Nouveau polypeptide, nucleoproteine basophile humaine 22.55, et polynucleotide codant ce polypeptide | |
| WO2001092328A1 (fr) | Nouveau polypeptide, proteine humaine 10.78 du gene cancerigene tre, et polynucleotide codant ce polypeptide | |
| WO2001094534A2 (fr) | Nouveau polypeptide, facteur humain de transcription 9.57, et polynucleotide codant ce polypeptide | |
| WO2001092519A1 (fr) | Nouveau polypeptide, chaine legere moderee de dyneine 20, et polynucleotide codant ce polypeptide | |
| WO2001072792A1 (fr) | Nouveau polypeptide, proteine humaine 13 analogue a l'ubiquitine, et polynucleotide codant pour ce polypeptide | |
| WO2002020743A1 (fr) | Nouveau polypeptide, i-kappa b kinase humaine 15, et polynucleotide codant ce polypeptide | |
| WO2001074894A1 (fr) | Nouveau polypeptide, proteine humaine de regulation 12 de la proteine phosphorylase, et polynucleotide codant pour ce polypeptide | |
| WO2002020583A1 (fr) | Nouveau polypeptide, facteur humain de transcription lcr-f19.02, et polynucleotide codant ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |